Chaoju Eye Care Holdings Limited disclosed that it bought back 28,500 ordinary shares on 2 July 2026 via on-market transactions at prices ranging between HK$2.46 and HK$2.51, for a total consideration of HK$0.07 million.

The repurchase leaves the company’s issued share capital unchanged at 705.18 million shares, as the acquired shares—intended for cancellation—have not yet been cancelled.

Key data from the filing

• Shares awaiting cancellation: 1.31 million, equivalent to roughly 0.19 % of the current issued share base. • Aggregate outlay for these yet-to-be-cancelled shares (repurchased between 2 April and 2 July 2026): about HK$3.50 million, implying an average buy-back price of roughly HK$2.68 per share. • Mandate utilisation: Since shareholders granted a new repurchase mandate on 12 May 2026, the company has bought back 925,500 shares, or 0.13 % of the shares outstanding on the mandate date. The authorised limit is 70.52 million shares, leaving more than 69.59 million shares available for further repurchase. • Moratorium: In line with Hong Kong Stock Exchange rules, Chaoju Eye Care cannot issue new shares or dispose of treasury shares until 1 August 2026.

All repurchases were approved by the board, executed on the Hong Kong Stock Exchange, and carried out in compliance with the exchange’s Main Board Rules and relevant regulations.